2
Announcements
Trials
Conditions
Other
1
Drug Classes
Anti-PD-1
16
Anti-CD20
10
Anti-VEGFR
10
Bcr-Abl inhibitor
10
MTOR inhibitor
10
Taxane
9
VEGFR inhibitor
9
Anti-HER2
7
Megakaryocyte growth factor
7
Anti-EGFR
6
EGFR inhibitor
6
Immunomodulatory drugs (IMiDs)
6
MEK inhibitor
6
ALK inhibitor
5
Antifolate
5
BTK inhibitor
5
Multikinase inhibitor
5
Nitrogen mustard
5
Anti-PD-L1
4
JAK inhibitor
4
Platinum agent
4
Proteasome inhibitor
4
Anti-RANKL
3
Asparagine-specific enzyme
3
BRAF inhibitor
3
HDAC inhibitor
3
Non-taxane microtubule dynamics inhibitor
3
Anthracycline
2
Anti-CD19-CD3 bispecific
2
Anti-CD30 ADC
2
Anti-CD38
2
Anti-CTLA-4
2
Aromatase inhibitor third generation
2
CDK inhibitor
2
CYP17 inhibitor
2
Erythrocyte growth factor
2
Factor IXa/Xa bridging
2
Fluoropyrimidine
2
Granulocyte colony-stimulating factor
2
Low molecular weight heparin
2
PARP inhibitor
2
Pyrimidine analog
2
SMO inhibitor
2
Alkylating agent
1
Anti-C5
1
Anti-CSF1R
1
Anti-EGFR-HGFR bispecific
1
Anti-GD2
1
Anti-HER2 ADC
1
Anti-IL-2R immunotoxin
1
Anti-IL-6
1
Anti-P-selectin
1
Anti-PDGFR
1
Anti-SLAMF7
1
Anti-dabigatran antibody fragment
1
Anti-vWF
1
Antimetabolite
1
Bcl-2 inhibitor
1
CXCR4 inhibitor
1
Cellular therapy
1
Chemotherapy protective agent
1
EDTA derivative
1
ERBB2 inhibitor
1
Estrogen receptor inhibitor
1
Factor Xa inhibitor
1
GnRH antagonist
1
HIF-2a inhibitor
1
Hemoglobin S polymerization inhibitor
1
Interferon
1
Iron chelating agent
1
Oncolytic viral therapy
1
PI3K alpha inhibitor
1
PI3K delta inhibitor
1
Profibrinolytic
1
Purine analog
1
ROCK2 inhibitor
1
Replacement therapy
1
SYK inhibitor
1
Second-generation nonsteroidal antiandrogen
1
Selective estrogen receptor modulator
1
Somatostatin analog
1
TGF-beta inhibitor
1
TRK inhibitor
1
Topoisomerase I inhibitor
1
Triazene
1
Vinca alkaloid
1
EDTA derivative
×
Other
×
Clear all
1 Announcement
2007-09-06
Dexrazoxane hydrochloride
Drug
Totect
(dexrazoxane hydrochloride)
· EDTA derivative